Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.2.1.22 (
cystathionine beta-synthase
)
965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cystathionine beta-synthase
(
CBS
) catalyzes the first irreversible step in the transsulfuration pathway and commits the toxic metabolite, homocysteine, to the synthesis of cysteine. Mutations in
CBS
are the most common cause of severe hereditary hyperhomocysteinemia. The molecular basis of the organ-specific pathologies associated with CBS deficiency is unknown as is the significance of the reported interaction between
CBS
and Huntingtin protein. In this study, we have used the yeast two-hybrid approach to screen for proteins that interact with
CBS
and have identified several components of the sumoylation pathway including Ubc9, PIAS1, PIAS3,
Pc2
, and RanBPM. We demonstrate that
CBS
is modified by the small ubiquitin-like modifier-1 protein (SUMO-I) under both in vitro and in vivo conditions. Deletion analysis of
CBS
indicates that the C-terminal regulatory domain is required for interaction with proteins in the sumoylation machinery. Sumoylated
CBS
is present in the nucleus where it is associated with the nuclear scaffold. The discovery that
CBS
is a target of sumoylation adds another layer to the complex regulation of this enzyme and reveals a previously unknown residence for this protein, i.e., in the nucleus.
...
PMID:Human cystathionine beta-synthase is a target for sumoylation. 1708 6